Porton Pharma Solutions Ltd. Class A

Porton Pharma Solutions Ltd. Class A

SSZSE:300363
21.72
CNY
+0.07
(+0.32%)
-0.28EPS
13.35BMarket Cap
Mar 22Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
2.03
2.52
2.5
3.18
2.75
2.47
2.93
3.9
5.75
12.98
6.73
5.55
6.39
6.7
Basic EPS, GAAP
0.28
0.32
0.27
0.41
0.25
0.26
0.35
0.61
0.97
3.7
0.49
-0.53
0.18
-0.18
Free Cash Flow per Basic Share
-0.2
-0.55
-0.76
0.23
0.31
0.05
0.33
0.21
-0.55
2.57
-0.92
-0.16
0.87
- -
Dividend per Share
0.02
0.07
0.12
0.13
0.18
0.16
0.13
0.16
0.15
0.24
1.15
0.56
0.06
0.12
Book Value per Share
1.18
1.98
2.65
3.02
3.24
5.31
5.65
6.25
7.31
10.99
10.62
9.53
9.85
9.29
Tangible Book Value per Share
1.09
1.78
2.03
2.42
2.37
4.69
5.04
5.64
6.56
9.9
9.58
8.52
8.85
8.29
Basic Weighted Avg Shares
361
392
409
418
430
479
530
532
540
542
545
543
535
543
Sales/Revenue/Turnover
734
987
1,021
1,327
1,184
1,185
1,551
2,072
3,105
7,035
3,667
3,012
3,420
3,640
Operating Margin (%)
18.31
17.88
14.62
19.86
15.97
11.17
14.41
19.79
20.53
32.5
9.25
-4.78
6.17
9.29
Depreciation Expense
18
30
56
79
116
125
117
131
192
260
349
401
426
- -
Net Income, GAAP
100
125
110
171
107
124
186
324
524
2,005
267
-288
96
-96
Effective Tax Rate (%)
16.36
17.09
19.83
20.89
17.64
16.13
7.13
11.15
13.35
13.78
28.81
- -
63.25
- -
Profit Margin (%)
13.64
12.71
10.81
12.9
9.07
10.51
11.96
15.66
16.87
28.51
7.28
-9.55
2.82
-2.63
Working Capital
-48
-75
-118
-205
-84
1,526
1,279
1,175
1,092
2,447
2,263
1,536
1,478
1,704
LT Debt
33
93
310
184
422
255
242
189
231
520
1,692
1,505
1,013
914
Total Equity
428
874
1,180
1,370
1,449
2,883
3,064
3,393
4,186
6,472
6,100
5,411
5,498
5,152
Return on Invested Capital (%)
16.17
11.74
6.24
7.08
3.92
4.01
4.86
8.58
11.12
31.6
2.47
- -
0.48
- -
Return on Capital (%)
17.82
14.06
8.34
9.65
6.67
5.9
6.21
9.49
13.38
34.06
5.04
- -
2.52
- -
Return on Common Equity (%)
26.47
20.25
11.44
14.25
8.08
5.85
6.24
10.05
14.21
40.17
4.52
-5.23
1.83
-1.85

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
545
308
349
LT Borrowings
428
494
451
LT Finance Leases
515
480
463
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
543
543
543
Market Capitalization
11,412
8,826
13,347

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
3,310
3,100
3,399
Cash, Cash Equivalents & STI
1,346
1,138
1,290
Accounts Receivable, Net
831
762
835
Inventories
791
851
944
Total Current Liabilities
1,786
1,552
1,695
Payables & Accruals
- -
- -
- -
ST Debt
545
308
349
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
20.04%
12.51%
1.61%
Free Cash Flow
-142.34%
-360.53%
-646.05%
Net Income, GAAP
7.39%
-16.75%
-133.48%
Sales/Revenue/Turnover
20.79%
24.84%
13.54%
Total Cash Common Dividend
36.3%
59.96%
-90.01%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
678
674
773
887
3,012
2025
801
820
- -
875
3,420
2026
886
904
975
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.17
-0.14
-0.07
-0.15
-0.53
2025
-0.01
0.06
- -
0.03
0.18
2026
0.05
-0.47
0.21
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.02
0.5
0.05
-0.02
0.56
2025
0.02
0.02
- -
0.01
0.06
2026
0.01
0.1
- -
- -
- -

Company Description

CEO
Nian Feng Ju
Full Time Employees
4,359
Sector
Health technology
Industry
Pharmaceuticals: other
Address
No.7, Yuntu Road Chongqing CH China 400714
IPO Date
Jan 29, 2014
Website
porton.cn
Business
Porton Pharma Solutions Ltd. (300363.SZ) is a leading contract development and manufacturing organization (CDMO) providing end-to-end services for small molecule drugs, peptide and oligonucleotide drugs, biologics and conjugates including antibody-drug conjugates (ADCs), antibody-oligonucleotide conjugates (AOCs) and peptide-drug conjugates (PDCs), and advanced therapy medicinal products such as gene and cell therapies; its core offerings encompass active pharmaceutical ingredients (APIs), drug substances (DS), drug products (DP), process development, GMP manufacturing from preclinical to commercial scale, and one-stop solutions for global pharmaceutical and biotech companies, research institutions, and clinical trials. Founded in 2005 and headquartered in Chongqing, China, with additional headquarters in Shanghai, the company operates R&D centers and production sites across China (including Sichuan, Jiangsu, Jiangxi, Hubei, and Suzhou), the United States (New Jersey), Slovenia, Belgium, Switzerland, and Denmark, employing over 4,900 staff globally and serving more than 1,000 clients including 80% of the top 20 pharmaceutical firms. Formerly known as Porton Fine Chemicals Ltd., it changed its name to Porton Pharma Solutions Ltd. in January 2018 to reflect its expanded CDMO scope. Recent developments include a strategic partnership with Dragon Sail Pharmaceutical in December 2024 to build an ADC drug development and production ecosystem through resource integration and supply chain sharing; a strategic alliance with Shanghai InnoStar Bio-tech in October 2024 for non-clinical research and end-to-end CDMO collaboration to accelerate drug development and enhance global market competitiveness; acquisition of 100% of Shanghai Gateway Pharmaceutical in 2022 to bolster CRO capabilities, R&D-production integration, and overall CDMO capacity; a strategic cooperation with Porton Biotech and Tianyu Life in September for NK cell therapy research, process development, GMP production, and clinical approval support; recognition as an excellent supplier by Mednovo Group in 2025 for radionuclide-drug conjugate (RDC) R&D support; opening of its small molecule platform headquarters and R&D center in Shanghai's Minhang District in May 2023 spanning 22,000 square meters; and Series-A financing closure for subsidiary Suzhou Porton Biologics in 2025 to expand commercial production of gene and cell therapy products including plasmids, viral vectors, and AAV processes.